Answers are grounded in this paper and cite their sources.
This analysis reports the clinical validity of FoundationOne Liquid CDx for detecting BRAF V600E mutations in colorectal cancer patients, suggesting its utility for targeted therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yaeger et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: